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Background: Combined modality treatment is the standard of care
for patients (pts) with unresectable stage III non-small cell lung
cancer. Dose escalation of radiotherapy is one strategy used to
improve locoregional control and survival, but it increases the risk of
both early and late treatment related toxicities.
Methods: From May 1996 to August 2004, a total of 112 stage III
non-small cell lung cancer pts were treated on 4 phase I/II or phase
II trials to assess the safety and feasibility of high-dose (60–90 Gy)
thoracic conformal radiotherapy. Patients who received 66 Gy
(n  88) were included in an analysis of late complications. Late
complications were defined as complications that developed or
persisted 90 days postradiotherapy. The classic lung toxicities of
radiation pneumonitis and fibrosis were not included in this analysis.
Results: Of the 88 patients included in this analysis of late compli-
cations, 21 patients (24%) developed a late complication and a total
of 28 late complications were observed. The late complications
were: pulmonary (n  5; bronchial stenosis [n  3] and fatal
pulmonary hemoptysis [n  2]), esophageal (n  6), cardiac (n  9),
osseous (n  6), and second primary tumor (n  2). The median
survival for all patients enrolled on the 4 trials (with 95% confidence
interval [CI]) was 24.7 months (18.1–30.4 months), and the 5-year
overall survival (with 95% CI) was 24% (16–32%). Data to assess
for radiographic evidence of local progression were available for 99
patients, and the rate of local progression was 43% (95% CI
34–53%).
Conclusions: High-dose thoracic conformal radiotherapy is feasible
and results in promising survival outcomes. Late complications
occur in a minority of patients.
Key Words: NSCLC, Radiotherapy, Concurrent Chemoradiother-
apy, Unresectable stage III NSCLC.
(J Thorac Oncol. 2009;4: 74–79)
Lung cancer is the leading cause of cancer death amongmen and women, accounting for more deaths than breast,
colon, and prostate cancer combined.1 In the United States in
2007, there will be an estimated 213,000 new lung cancer
diagnoses and approximately 160,000 deaths.1 Non-small cell
lung cancer (NSCLC) comprises approximately 85% of lung
cancer diagnoses and of these, 30 to 40% of patients present
with stage IIIA/B disease.2 The standard of care for patients
with unresectable stage III disease and a good performance
status consists of systemic chemotherapy and thoracic radia-
tion therapy (TRT). Treatment with the combination of che-
motherapy and radiotherapy results in 3- and 5-year survival
rates of 15 to 25% and 10 to 20%, respectively.2 Although
combined modality therapy improves survival when com-
pared with radiotherapy alone, loco-regional and distant re-
currences continue to be problematic.
A variety of different chemotherapeutic and radiation
strategies have been investigated to improve outcomes in
unresectable stage III NSCLC. Phase III trials revealed that
concurrent chemotherapy and TRT is more efficacious than
sequential.3,4 Radiation techniques such as dose intensifica-
tion and escalation have also been studied, but the current
standard dose of TRT has remained unchanged for many
years. The current standard radiation dose for inoperable lung
cancer was established in 1987 by Radiation Therapy Oncol-
ogy Group (RTOG) trials 7301 and 7302 that demonstrated
improved local control with a radiation dose of 60 Gy
compared with lower doses.5 These trials used two-dimen-
sional (2-D) treatment planning wherein the tumor volume
was defined on kilovoltage radiographs. The efficacy of this
dose has been questioned; evidence from Arriagada et al.6
demonstrated a disappointing 1 year local regional tumor
control rate of 17% for unresectable NSCLC patients treated
with 65 Gy of TRT alone. In this same trial, those treated with
chemotherapy pre- and post-TRT (65 Gy) also demonstrated
a poor 1 year local regional tumor control rate (15%). This
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study strongly suggests that the current standard radiation
dose is inadequate.
In the interval since RTOG trials 7301 and 7302, three-
dimensional thoracic conformal radiation therapy (TCRT) and
modern chemotherapy have been developed. Three-dimen-
sional TCRT has improved tumor targeting which allows for
more accurate delivery of radiation to tumor and reduced
radiation exposure to organs at risk within the thorax. At the
University of North Carolina, we evaluated various dose
escalation strategies in several Phase I and II clinical tri-
als.7–13 The prescribed dose of three-dimensional TCRT in
these trials ranged from 60 to 90 Gy. The intensification of
therapy and specifically the TCRT dose increases the risk of
acute as well as late treatment-related toxicities. This analysis
highlights the unclassical pulmonary toxicities and does not
detail the classic lung toxicities of radiation pneumonitis and
fibrosis. We herein report the long term follow-up and late
complications of patients treated with high-dose three-dimen-
sional TCRT for unresectable stage III NSCLC.
METHODS
Eligibility
All patients were required to have histologically or
cytologically confirmed unresectable stage III NSCLC and
determined to be appropriate candidates for combined mo-
dality therapy. Initial staging consisted of a chest radiograph,
staging computed tomography (CT) scan (including liver and
adrenal glands), radionuclide bone scan and/or positron emis-
sion tomography (PET) scan, and a brain CT or magnetic
resonance image. All patients were evaluated by a medical
oncologist, thoracic surgeon, pulmonologist, thoracic radiol-
ogist, and radiation oncologist and discussed at a multidisci-
plinary thoracic oncology tumor board.
All patients were required to have an Eastern Cooper-
ative Oncology Group (ECOG) performance of 0–1, al-
though in our early experience a few patients with ECOG 2
were treated in this fashion. Patients could not have received
prior radiation and/or chemotherapy for NSCLC or prior
chest radiotherapy. Other inclusion criteria were preserved
bone marrow, renal, and hepatic function. Pulmonary func-
tion test required a forced expiratory volume 1 second (FEV1)
of 800 or 1200 ml at baseline or an estimated post three-
dimensional TCRT FEV1 800 ml. The details of the calcu-
lation of post-TRT FEV1 have been previously published.8
Patients with malignant involvement of the supraclavicular
lymph nodes or malignant pleural effusion were excluded. In
addition to meeting these inclusion criteria, patients included
in the analysis of late complications were required to receive
a minimum TCRT dose of 66 Gy. All of these trials were
reviewed by the protocol review committee of Lineberger
Comprehensive Cancer Center at the University of North
Carolina, and approved by the Institutional Review Board of
the participating institutions. This retrospective analysis was
approved by the Institutional Review Board at the University
of North Carolina.
Treatment Overview
All patients received two cycles of carboplatinum-
based induction chemotherapy. The efficacy and toxicity of
the induction chemotherapy regimens have been previously
published.7–13 Three of the four trials employed carboplatin
and paclitaxel concurrent with radiotherapy, and one trial
used hyperfractionated radiotherapy without concurrent che-
motherapy. Radiation treatment planning for the three trials
has been previously published.7–13 The prescribed radiation
dose ranged from 60 to 90 Gy and was delivered either in
once daily fractions of 200 cGy (n  98) or 125 cGy twice
daily (minimum 6 hours between fractions; n 14). Seventy-
six patients underwent CT in the treatment position prior to
chemotherapy. The remaining 36 patients underwent a plan-
ning CT after the second cycle of chemotherapy. Initial fields
included the prechemotherapy gross tumor volume, ipsilat-
eral and contralateral (elective) mediastinum as identified on
CT scans with a 0.5 to 1 cm margin. The planning target
volume (PTV) was the clinical target volume plus a margin
added to compensate for variability in treatment setup,
breathing, or motion during treatment. In general, the PTV
included the clinical target volume plus a 1.0 cm expansion at
all borders. The initial PTV received between 40 and 50 Gy
depending on the trial and dose-escalation schema. The boost
treatment volume included the postinduction tumor as defined
on CT scans and regions where nodes were initially positive
(size1 cm on CT, and/or PET or mediastinoscopy positive).
The quoted doses were the minimal dose to the PTV with the
inhomogeneities kept within 5%. The V20 limitation was 35%
(no more than 35% of the lung volume could receive 20
Gy). The V20 was calculated using the combined lung volume
minus the gross tumor volume. There was no dose limit for
the heart or esophagus; however, it was strongly encouraged
that the entire heart (and/or left ventricle) not receive60 Gy
and that the full circumference of the esophagus for greater
than a 6 cm length not receive 60 Gy. After treatment,
routine clinical follow-up was scheduled every 2 months for
1 year and then every 3 months for 1 year, and then after 2
years patients were seen every 6 months for 3 years, and then
yearly. A chest radiograph was done with each visit. A
staging CT was done approximately 8 weeks after completion
of radiotherapy, 6 months after therapy, and at the discretion
of the treating physician.
Statistical Methods
The Kaplan-Meier (or product limit) method was used
to estimate the time to event functions of time to toxicity and
overall survival. Time to toxicity was defined as the time
from the date of enrollment to the date of the first late (greater
than 90 days) toxicity or date of death, or of last contact.
Overall survival was defined as the time from the date of
enrollment to the date of death or the date of last contact.
Fisher’s exact test was used for data categorized into 2 by 2
contingency tables. The nonparametric Jonckheere-Terpstra
method was used to test for ordered differences among
categories for larger contingency tables. With this test, the
null hypothesis is that the distribution of the response does
not differ across ordered categories. The Wilcoxon rank sum
test (using Van der Waerden normal scores) was used for
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two-group comparisons. Exact 95% confidence intervals
were calculated for reported proportions (or percentages) of
interest. Statistical analyses were performed with SAS statis-
tical software, Versions 9.1, SAS Institute Inc., Cary, NC.
RESULTS
Patient Characteristics
From May 1996 to August 2004, 112 unresectable
stage III NSCLC patients were treated on these clinical trials.
The 88 patients who received 66 Gy were included in an
analysis of late complications (Table 1). Twenty-four patients
did not receive 66 Gy for various reasons: prescribed
protocol treatment of66 Gy (n 3), withdrawal of consent
(n  3), interval progression of disease (n  8; 3 progressed
locally, 2 distant, 3 unknown), worsened medical illness (n 5),
hypersensitivity reaction to paclitaxel (n 1), death (n 1), or
unknown (n  3). Among those who received 66 Gy, the
median TCRT dose was 74 Gy (range, 66–90 Gy), and 41
patients (47%) received this dose. The median age for all
patients was 59 years (range, 36–82 years), 71 patients (63%)
were male, 86 patients (77%) were white, and 54 (48%) had
stage IIIA disease, whereas 58 (52%) had stage IIIB disease.
Only six patients underwent 18-fluorodeoxyglucose-PET-CT
scan as part of the initial staging workup. This is largely due
to the fact that PET was not yet standard procedure for
staging workup at the time several of these trials were
written. All patients had an ECOG performance status of 0–1.
The most common histology was adenocarcinoma (50%).
Late Toxicity
Late toxicities were defined as those that occurred or
persisted 90 days after completion of radiotherapy. Of the
88 patients who received 66 Gy included in this analysis,
21 patients (24%) developed a late complication and a total of
28 late complications were observed (Table 2). Of note, the
classic lung toxicities of radiation pneumonitis and fibrosis
were not included in this analysis. The late complications
included: bronchial stenosis (n  3, 3.4%), fatal pulmonary
hemoptysis (n  2, 2.3%), esophageal stricture (n  6,
6.8%), vertebral or rib insufficiency fracture (n  6, 6.8%),
pericardial effusion (n  3, 3.4%) or constrictive pericarditis
(n  2, 2.3%), myocardial infarction (n  4, 4.5%), and
second primary tumor within the radiation field (n 2, 2.3%;
one sarcoma and one small cell lung cancer). The sarcoma
was diagnosed approximately 8 years after completion of 74
Gy and the small cell lung cancer was diagnosed approxi-
mately 4 years after completion of 86 Gy. Although these
malignancies occurred within the field of radiation, it is
possible they were not radiation-induced. Two other patients
developed a second primary malignancy outside of the radi-
ation field (one liver carcinoid and one second primary
NSCLC) that was not considered a late complication of
radiotherapy.
The three patients with bronchial stenosis presented
with symptoms including cough, dyspnea, and recurrent
infection; lobar collapse was seen on diagnostic and ther-
apeutic bronchoscopy. All of the patients with pericardial
disease presented with shortness of breath and varying de-
grees of other heart failure symptoms. One of the two patients
with constrictive pericarditis required a pericardial window
and recovered, the other died secondary to distant relapse.
Two of the three patients with pericardial effusion improved
with pericardiocentesis; one improved spontaneously. The
patients with esophageal stenosis presented with dysphagia
and were treated with endoscopic esophageal dilation. Of the
four myocardial infarctions, one was fatal. Three of four
patients with MI underwent successful cardiac bypass.
Although these MI’s occurred postradiotherapy, it is pos-
sible that they occurred as a result of pretreatment condi-
tions such as tobacco use and other cardiac risk factors. In
total, there were 5 fatal conditions believed to be radiation
induced: hemoptysis (n  2), MI (n  1), sarcoma (n  1),
and small cell lung cancer (n  1).
Two cases of fatal hemoptysis were observed. One
patient was a 41-year-old man with stage IIIB (T4N1) poorly
differentiated NSCLC who initially presented with hemopty-
sis and received 90 Gy TRT. One hundred and ten days after
completion of the TRT, an episode of massive fatal hemop-








Age (yr), median (range) 58.8 (36–82) 58.5 (36–82)
Gender (male:female) 71:41 56:32
Race (white:non-white) 86:26 67:21
Stage (IIIA:IIIB) 54:58 42:46
ECOG PS (0:1) 51:61 46:42
Histology (%)
Adenocarcinoma 50% (56/112) 47% (41/88)
Squamous 36% (40/112) 38% (33/88)
Other 14% (16/112) 16% (14/88)
n, number; ECOG, Eastern Cooperative Oncology Group; PS, performance status;
TCRT, thoracic conformal radiation therapy.
TABLE 2. Late Complications in Patients Receiving 66 Gy
Cases
(n  88)
% of Total Late
Complications
(n  28) Onset (mo)
Pulmonary
Bronchial stenosis 3 11 2, 6, 7
Fatal hemoptysis 2 7 4, 13
Esophageal
Stricture 6 21 3, 3, 3, 10, 40, 65
Osseous
Vertebral/rib fracture 6 21 2, 8, 16, 17, 21, 36
Cardiac
Pericardial diseasea 5 18 2, 15, 33, 41, 90
Myocardial Infarction 4 14 21, 33, 33, 65
Oncologic
Second primary 2 7 48, 95
a Pericardial effusion (n  3) and constrictive pericarditis (n  2).
n, number.
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tysis occurred in the emergency department. An autopsy was
performed and did not reveal an identifiable origin of bleed
and no local residual tumor was identified. The second patient
was a 39-year-old man with stage IIIA (T2N2) NSCLC
(squamous cell) who initially presented without hemoptysis,
and received 82 Gy in 41 fractions over 80 days rather than
the expected 57 days, due to grade 3 esophagitis. Four
hundred days after completion of TRT, he experienced mas-
sive fatal hemoptysis, observed in the medical intensive care
unit. An autopsy was performed, and revealed severe left
upper lobe pulmonary fibrosis with chronic radiation-induced
vasculopathy; no residual tumor was identified.
When comparing those who did not experience a late
complication to those who did experience a late complication,
both groups received a median TCRT dose of 74 Gy, but
those who had a late complication had a significantly higher
interquartile range (IQR) (74 Gy, IQR 74–86 versus 74 Gy,
IQR 74–78, respectively; p  0.03) (Table 3 and Figure 1).
Those who had a late complication also had a trend toward
younger median age (53 years versus 59 years, respectively;
p 0.07). The other patient characteristics were quite similar
(Table 3). Pulmonary and esophageal complications tended to
occur earlier after completion of radiotherapy, whereas car-
diac, osseous, and second primary tumors tended to occur
later (Table 2).
Overall Response and Survival
Overall survival analysis was performed based on in-
tent to treat and included all patients enrolled on the 4 clinical
trials (n  112). Of a total of 112 patients, 92 have died and
20 were still alive at the time of analysis (Figure 2). The
median follow-up time for survivors was 7.5 years, and 9
survivors were alive more than 8 years from date of enroll-
ment. The median survival (with 95% CI) was 24.7 months
(18.1, 30.4), and the 1-, 3-, and 5-year overall survival (with
95% CI) was 70% (60, 77%), 35% (27, 44%), and 24% (16,
32%), respectively.
For the 112 patients treated on these trials, data on
response were available for 94 patients; the overall response
rate after combined modality therapy was 56% (95% confi-
dence interval [CI] 46%, 66%); complete response 5%, par-
tial response 51%. The disease control rate (complete response,
partial response, and stable disease combined) was 89% (95%
CI 83–96%). Data to assess for radiographic evidence of local
progression were available for 99 patients, and the rate of local
progression was 43% (95% CI 34–53%). Data on distant recur-
TABLE 3. Comparisons of Patients Who Had a Late Toxicity
to Those Who Did Not
Had a
Late Toxicity
Did Not Have a
Late Toxicity P
Gender (male) 14/21 63% 42/67 62% 0.79
Race (Caucasian) 15/21 71% 52/67 78% 0.77
Stage (III-B) 8/21 38% 38/67 57% 0.21
ECOG (1) 7/21 33% 35/67 54% 0.14
Con-Chemo (yes) 2/19 11% 10/59 17% 0.72
Age (median, range) 53 (36–81) 59 (39–82) 0.07a
XRT (median, IQR) 74 (IQR 74–86) 74 (IQR 74–78) 0.03b
Response 0.78
CR 1 (5%) 4 (6%)
PR 10 (50%) 36 (55%)
SD 8 (40%) 20 (30%)
PD 1 (5%) 6 (9%)
Histology 0.84
Adenocarcinoma 9 (44%) 32 (48%)
Squamous 9 (43%) 24 (36%)
All others 3 (14%) 11 (16%)
a Borderline significant.
b Significant at   0.05.
ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; XRT,
concurrent chest radiation; CR, complete response; PR, partial response; PD, progres-
sive disease; SD, stable disease.
FIGURE 1. Histogram that compares the distribution of pa-
tients who had late toxicities to those who did not by radia-
tion dose. The distributions are similar (with the same mini-
mum, median, and maximum doses) except more patients
who received 82, 86, and 90 Gy dose levels in the ‘Yes’ ‘Had
Toxicity’ group (p  0.02).
FIGURE 2. Overall survival including 95% confidence
bands for all patients (n  112).
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rence were available for 103 patients, and 12.6% (n  13)
developed recurrent disease in the brain only.
DISCUSSION
This analysis demonstrates that high-dose thoracic con-
formal radiotherapy (TCRT) is feasible in patients with un-
resectable stage III NSCLC, and late complications occurred
in a minority (24%) of patients. Other groups have investi-
gated the toxicity of high dose three-dimensional TCRT in
Phase I and II trials (Table 4), and the incidence of late
complications seen on this study is consistent with previous
studies.14–17 The cumulative data from these trials indicate
that the primary late toxicities of high dose TRT are pulmo-
nary and esophageal.
In unresectable stage III NSCLC, the goal of TRT is to
control local disease and subsequently prolong survival.
More aggressive TCRT may be beneficial; however, it is
clear that dose escalation alone is not sufficient to eliminate
the problem of local recurrence, and its effect on long term
survival.8 Local failures, observed in 43% of the patients in
this analysis, will continue to be problematic. Radiation
resistance, faulty tumor localization, and treatment precision
could all be factors contributing to the problem of local
recurrence. Technologic advances in treatment planning and
tumor targeting such as the use of intensity modulated radio-
therapy will aid in optimal delivery of radiation with minimal
risk to vital structures. Improved tumor imaging, using tech-
niques such as PET scan, will improve staging and better
localize malignant tissue within the thorax. PET imaging may
also better exclude patients who have occult metastatic dis-
ease. These technologic advances alone may lead to improve-
ments in overall survival on future combined modality clin-
ical trials.
In our opinion, this rate of late toxicities is acceptable
given the poor prognosis for patients with unresectable stage
III NSCLC, and the promising median survival (24.7 months)
and 5-year overall survival rate (24%) observed in this
analysis. However, this cohort of patients may represent a
select group of patients with unresectable stage III disease
who received their treatment on a clinical trial in a multidis-
ciplinary thoracic oncology clinic. The dose and volume
constraints of the high dose three-dimensional TCRT in our
cohort limited enrollment based on tumor volume, anatomic
location (e.g., superior sulcus tumors were excluded) and to
patients without supraclavicular lymph node involvement.
However, other eligibility criteria used in our trials such as
performance status, staging requirements, and organ function
were similar to other trials performed in this patient popula-
tion.18–21 The high dose TCRT investigated in these trials
may have a higher rate of toxicity in different clinical settings
or a more heterogeneous patient population.
An ongoing phase III trial is comparing TCRT at the
standard dose of 60 Gy to treatment at a higher dose of 74 Gy
with concurrent chemotherapy. Patients enrolled on this trial
will receive concurrent chemotherapy (weekly carboplatin
area under curve  2 and paclitaxel 45 mg/m2) and TRT to
either 60 or 74 Gy. After completion of the concurrent
chemoradiotherapy, all patients will then receive 2 cycles of
systemic chemotherapy (carboplatin area under curve  6
and paclitaxel 200 mg/m2) every 3 weeks. This phase III trial
is being performed in cooperation by Cancer and Leukemia
Group B, RTOG, and the North Central Cancer Treatment
Group. This trial will provide additional information about
the efficacy, as well as the acute and late toxicities of high
dose three-dimensional TCRT Until the results of this trial
available this treatment approach should be considered inves-
tigational.
In conclusion, higher TCRT doses are accompanied by
the risk of late complications, but this strategy appears to be
tolerable and result in promising survival outcomes. Unfor-
tunately, the majority of patients with unresectable stage III
disease will die of progressive disease within 3 years of
diagnosis. A combination of strategies that optimize the
selection of patients for combined modality therapy and
maximize the therapeutic benefit of radiation, chemotherapy,
and potentially targeted therapies are needed.
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